Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety

Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer

(2014) Yasutsuna Sasaki et al.   CANCER SCIENCE

Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer

(2014) Ewa Mrózek et al.   Clinical Breast Cancer

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors

(2013) David Groheux et al.   CANCER

Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using 18F-FDG PET in luminal HER2-negative breast cancer

(2013) Olivier Humbert et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

nab-Paclitaxel mechanisms of action and delivery

(2013) Denise A. Yardley   JOURNAL OF CONTROLLED RELEASE

Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study

(2013) Yoo-Joung Ko et al.   LANCET ONCOLOGY

Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

(2012) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

(2012) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: A clinical review

(2011) J. Chirgwin et al.   BREAST

Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis

(2011) Yuting Wang et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer

(2011) Masashi Ando et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

18F-Fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response

(2011) Shigeto Ueda et al.   International Journal of Clinical Oncology

Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients with Primary Breast Cancer

(2011) H. Iwata et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer

(2010) A. Schneeweiss et al.   ANNALS OF ONCOLOGY

A Phase II Trial of Dose-Dense Neoadjuvant Gemcitabine, Epirubicin, and Albumin-Bound Paclitaxel With Pegfilgrastim in the Treatment of Patients With Locally Advanced Breast Cancer

(2010) Denise A. Yardley et al.   Clinical Breast Cancer

A Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound Paclitaxel Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide in Locally Advanced Breast Cancer

(2010) André Robidoux et al.   Clinical Breast Cancer

Phase II Evaluation of Nanoparticle Albumin–Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

(2009) Michael G. Teneriello et al.   JOURNAL OF CLINICAL ONCOLOGY

Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

(2009) William J. Gradishar et al.   JOURNAL OF CLINICAL ONCOLOGY

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

(2009) R. L. Wahl et al.   JOURNAL OF NUCLEAR MEDICINE

Protein nanoparticles as drug carriers in clinical medicine

(2008) Michael J. Hawkins et al.   ADVANCED DRUG DELIVERY REVIEWS

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER